Replies to post #2896 on Galectin Therapeutics Inc. (GALT)

[gss2003]

Yes, but they can sell for access to GR-MD-02, patents and then have a secondary milestone payment if the CX trial is successive. Somewhat like NVS and TBRA.

[Coolec78]

Isn't agressive takeover possible, like Martin Shake like and KBIO case? Then negotiations are not necessary. Price will be high though.

[Tekterra]

They do have a billionaire backing them. So management might not be in a rush to sell or make a poor deal. They have releases a lot of data recently, and it's no doubt drawing a lot of attentions. But to sell out so soon may not be the case just yet.

Management have also clearly stated they are seeking partnership. I can see some negotiations happening at this point after their data release.

While back, an article mentioned institutions getting back in early which bumped the stock price up substantially compare to just months ago in red under one dollar. Those guys are in it for the same reason that they believe GALT has something worth a while.

I mean going from under a dollar to current level without news isn't just some average Joe trading. In with the professionals often times aren't a bad idea.

There was also some talks that their Phase II trails are designed in a way that may qualify for FDA approval which means potentially hitting the market as early as 2018.

Generally, if one person was saying it, that might just be that one person's opinion. But, when this heats up and more and more people are saying it, there is probably some weight behind what's being said.